PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 38/55, 38/06, A61P 9/14 — A1

(11) International Publication Number: **WO 00/64470**

(43) International Publication Date: 2 November 2000 (02.11.00)

(21) International Application Number: PCT/SE00/00756

(22) International Filing Date: 19 April 2000 (19.04.00)

(30) Priority Data:

9901442-5	21 April 1999 (21.04.99)	SE
9904419-0	3 December 1999 (03.12.99)	SE

(71) Applicant *(for all designated States except US)*: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: GUSTAFSSON, David [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: ASTRAZENECA AB; Global Intellectual Property, Patents, S-151 85 Södertälje (SE).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: A PHARMACEUTICAL FORMULATION COMPRISING A LOW MOLECULAR WEIGHT THROMBIN INHIBITOR AND ITS PRODRUG

(57) Abstract

According to the invention there is provided a kit of parts comprising: (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and (b) a pharmaceutical formulation including a produg of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, which components (a) and (b) ar each provided in a form that is suitable for administration in conjunction with the other, as well as the use of such a kit of parts in the treatment of a condition in which inhibition of thrombin is required or desired.